Is ENOV or HSCS more undervalued in 2026?

CirclFi compares Enovis Corporation (ENOV) and HeartSciences Inc. (HSCS) using 13 institutional-grade valuation models. ENOV has a Quality of Company score of 5.0/10 while HSCS scores 4.2/10.

Which is a better buy — ENOV or HSCS?

Compare intrinsic values from 13 independent models against current market prices. CirclFi also calculates Value Trap scores. This is not financial advice — conduct your own analysis.

How do ENOV and HSCS valuations compare?

ENOV at $22.68 and HSCS at $1.67 are compared across Bayesian DCF, EPV, EROIC Spread, First Chicago, Markov DDM, and 8 additional models.

ENOV vs HSCS Valuation Comparison 2026 — Intrinsic Value Analysis

ENOV

Orthopedic, Prosthetic & Surgical Appliances & Supplies

Enovis Corporation

Quality

5.0

out of 10

Value Trap

LOW

Price

$22.68

Last close

Models

10/13

Active

HSCS

Orthopedic, Prosthetic & Surgical Appliances & Supplies

HeartSciences Inc.

Quality

4.2

out of 10

Value Trap

LOW

Price

$1.67

Last close

Models

11/13

Active

Model-by-Model Comparison

Model	Type	ENOV Fair Value	ENOV Upside	HSCS Fair Value	HSCS Upside
Bayesian DCF	Intrinsic	$13.78	-39.2%	$1.00	-40.4%
Earnings Power Value	Intrinsic	$4.62	-79.7%	$1.36	-31.7%
EROIC Spread	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
First Chicago	Scenario	$•••.••	••.•%	$•••.••	••.•%
ML-RIV	Intrinsic	$•••.••	••.•%	$•••.••	••.•%
Dynamic NAV	Asset-Based	$•••.••	••.•%	$•••.••	••.•%
PWERM	Option-Based	$•••.••	••.•%	$•••.••	••.•%
Regime Cross-Sectional	Relative	$•••.••	••.•%	$•••.••	••.•%
Sentiment SOTP	Hybrid	$•••.••	••.•%	$•••.••	••.•%
CUCE Ensemble	Ensemble	$•••.••	••.•%	$•••.••	••.•%
FTNN Topology	Relative	$•••.••	••.•%	$•••.••	••.•%

🔒

Unlock Full 13-Model Comparison

Access all valuation models for ENOV vs HSCS — including EROIC Spread, First Chicago, Markov DDM, PWERM, and 7 more.

Access Full Analysis — From $27/mo →

ENOV vs HSCS — Which Stock Is More Undervalued?

ENOV scores higher with a 5.0/10 quality rating vs HSCS's 4.2/10. Both stocks are analyzed daily using SEC EDGAR filings across 13 independent models.

Comparing Enovis Corporation (ENOV) and HeartSciences Inc. (HSCS) across 13 institutional-grade valuation models reveals how each company's intrinsic value stacks up against its market price. CirclFi's engine processes SEC EDGAR 10-K and 10-Q filings, FRED macroeconomic data, and GDELT news sentiment to generate independent fair value estimates daily.

ENOV currently trades at $22.68 with a QOC of 5.0/10, while HSCS trades at $1.67 with a QOC of 4.2/10.

Both companies are analyzed with models spanning intrinsic (Bayesian DCF, EPV), scenario-based (First Chicago), regime-switching (Markov DDM, RCMH-DCF), machine learning (ML-RIV, FTNN Topology), and ensemble methods (CUCE).